Analysis on clinical therapeutic efficacy of 49 cases with hilar cholangiocarcinoma
- Author:
Ming-An ZHONG
1
Author Information
1. Department of General Surgery
- Publication Type:Journal Article
- Keywords:
Bile duct neoplasms;
Bilirubin;
Retrospective studies;
Treatment dutcome
- From:
Tumor
2007;27(9):744-746
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the related factors for the therapeutic efficacy of hilar cholangiocarcinoma. Methods: A retrospective clinical analysis was performed on the clinical data from 49 patients with hilar cholangiocarcinoma. Results: The mean survival time was 19.5 months, 8.79 months, and 5.44 months for the total 49 patients who received radical resection, palliative resection, and drainage operation, respectively. The mean survival time was 23.5 months, 9.37 months, and 2.90 months for patients at AJCC TNM stage I and II, III, and IV (IVa and IVb), respectively. The mean survival time was 3.62 months for patients with a total bilirubin level more than 300 μmol/L or 14. 74 months for those patients with a total bilirubin level less than 300 μmol/L. The mean survival time was 5.68 months, 11.59 months, and 22.17 months for patients whose total serum bilirubin level was more than 40 μmol/L, between 20 to 40 μmol/L, and less than 20 μmol/L one week after operation, respectively. Conclusion: TNM stage and curative resection degree are the main related factors influencing the therapeutic efficacy of hilar cholangiocarcinoina. The decreased degree in the serum level of total bilirubin before and after surgery has the potential to be used as a marker to predict the long-term therapeutic efficacy of hilar cholangiocarcinoma.
